Develops and commercializes non-invasive cancer screening tests. Offers Cologuard, a stool-based DNA test for colorectal cancer screening. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 6.2× for every dollar of annual revenue.
Analysts' average target sits 11% below today's price.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 16% a year on average.
The company sells $3.2B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $207.9M against $3.2B in annual sales.
The stock trades 11% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.